Remove 2023 Remove Hospital Remove Nuclear Medicine Remove Radiopharmaceuticals
article thumbnail

IMV: Nuclear medicine procedure volumes decrease

AuntMinnie

Total nuclear medicine patient study volumes decreased by 5.7% between 2021 and 2023, with a 10.7% decrease in hospital-based studies and a 2.5% Two-year compound annual growth rates (CAGR) between 2021 and 2023 show an overall average 2.9% and non-hospital procedures increasing by 1.2%. Of these, 5.8

article thumbnail

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7% from 1,401 estimated PET scans per system in 2022 to 1,495 in 2023. Davin Korstjens. physicians reading PET scans per site.

PET Scan 116
article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. He also helped lead the theranostics conference at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 midwinter meeting. However, few freestanding theranostics centers exist today. Hope added. Hope added.

article thumbnail

Umar Mahmood, MD, PhD, Receives First Annual SNMMI Minoshima-Pappas Transformational Leadership Award

Imaging Technology

Mahmood was presented the award by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) at its 2023 Annual Meeting. Award recipients will have initiated, developed, and successfully implemented unique and significant transformative value within the field of nuclear medicine and molecular imaging.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.